Altimmune Inc

In the Stage 4 decline, ALT remains in a lower-high/lower-low sequence below all major EMAs. Price action is sideways and indecisive around the 9/21 EMA band with RSI neutral. Medium-term structure is bearish while the long-term trend stays up. Execution calls for trimming into rallies up to the EMA resistance zone.

• ↑$519M cash covers expenses through 2027 and 2029 pemvidutide readouts, reducing near-term financing risk.
• ↑Phase 2 pemvidutide trials for AUD and MASH show significant efficacy trends, opening multi-indication potential.
• ↓Zero revenues last quarter underscore reliance on equity raises and potential dilution.